Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivax plus sunitinib versus sunitinib alone in first-line metastatic renal cell carcinoma
2007-002556-41Phase 2Completed
- Sponsor
- TriMed Biotech
- Start
- Jan 2008
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Trivax in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by TriMed Biotech. Primary endpoint: Tumor progression per RECIST. Started Jan 2008; status: completed.
02
Drugs
Trivax
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2007-002556-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002556-41.